biote Corp.
BTMDDrugs in Pipeline
7
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
RY_SW01 cell injection
Lupus Nephritis
Basic treatment
Systemic Sclerosis
IMA402 (Phase Ia)
Refractory Cancer
Endoxana, Leukine, IMA910
Colorectal Carcinoma
KL003 Cell Injection Drug Product
Transfusion-dependent Beta-Thalassemia
donor-derived NK cell infusion
Non-small Cell Lung Cancer
Endoxana, IMA901, Leukine
Renal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RY_SW01 cell injection | Phase 2 | Lupus Nephritis | - | - |
Basic treatment | Phase 2 | Systemic Sclerosis | - | - |
IMA402 (Phase Ia) | Phase 2 | Refractory Cancer | - | - |
Endoxana, Leukine, IMA910 | Phase 2 | Colorectal Carcinoma | - | - |
KL003 Cell Injection Drug Product | Phase 2 | Transfusion-dependent Beta-Thalassemia | - | - |
donor-derived NK cell infusion | Phase 2 | Non-small Cell Lung Cancer | - | - |
Endoxana, IMA901, Leukine | Phase 2 | Renal Cell Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in biote Corp.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in biote Corp.'s (BTMD) pipeline across Phase 2. Its lead program is RY_SW01 cell injection (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is biote Corp.'s next FDA catalyst?→
biote Corp.'s (BTMD) next tracked catalyst is a Earnings expected November 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BTMD biotech catalysts?→
Add BTMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow biote Corp.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.